ⓘ PCP site 2
PCP site 2 is a binding site that was identified as a high-affinity target for phencyclidine, an anesthetic and dissociative hallucinogen that acts primarily as an NMDA receptor antagonist. The site is distinct from the PCP binding site on the NMDA receptor and the common/main sites on the monoamine transporters. It is associated with monoamine reuptake inhibition, and it has been suggested that the site may be an allosteric/regulatory site of the monoamine transporters.
RTI-4793-14 HBMP, a ligand with high affinity for site 2 PP and high selectivity to this page on the website for the RFA 1, was developed. By analogy with the PCP, RTI-4793-1 inhibition of monoamine reuptake with moderate potency, but unlike PCP has very low potency as an NMDA receptor antagonist. It shows the profile of the serotonin–norepinephrine–dopamine reuptake inhibitor SNDRI. Although it was the conclusion associated with binding to PCP site 2, subsequent studies found that RTI-4793-14 also has a considerable affinity to the pic, were not typical in Sert or not, but maybe tie them in a similar way, and these interactions could potentially explain the inhibition of monoamine reuptake as an alternative to PCP site 2.